June #135 : Seeing Double - by Liz Highleyman

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Jagged Little Pills

Happy Feet

Bunny Business




Playing the Percentages

Soul Survivors

B Careful

In the Running

Seeing Double

Write of Passage

Salad Daze

From Here to Paternity

Summer Share




Papa, Can You Hear Me?

Outside Chance

Send Us the Bill

Climb Every Mountain

Farewell Tour

Hot Dates-June 2007

Agent Provocateur

Mixed (Up) Media

Another AIDS Movie for Philadelphia

Say What?!-June 2007

Attention, K-Y Shoppers

The Next Best Thing to Being There

Getting Crafty

Baggage Claim




Editor's Letter-June 2007

Mailbox-June 2007

Catch of the Month—June 2007



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV



email print

June 2007


Seeing Double

by Liz Highleyman

Treatments for hepatitis C begin to mimic those for HIV

For the estimated one-third of HIV-positive folks who also have hep C (HCV), watching drug development is a must. Standard HCV therapy—pegylated interferon (to help the immune system fight C) plus ribavirin (to curb relapse)—has side effects so bad they feel like “the flu from hell,” and works in fewer than half of cases. Experimental meds attack HCV itself, disrupting its reproduction (as HIV meds do to HIV) while causing fewer side effects. The hope: drugs with more oomph but fewer ughs.

One that could be approved in late 2008 is Vertex’s HCV protease inhibitor (PI), telaprevir (VX-950). Alone or with interferon, telaprevir suppresses HCV and by itself hasn’t caused nasty side effects. Other novel meds, including two more PIs and two that inhibit another HCV enzyme, polymerase, are also close to approval.

Further, researchers have found a protein, claudin-1, that HCV uses to enter cells, offering another possible future drug target. As with HIV meds, combining drugs would add punch and delay drug resistance. So look for hep combos that tackle HCV at various life-cycle stages.

In grimmer news, recent studies confirm HCV transmission via sex, not only shared needles. First, outbreaks erupted among HIV-positive gay men in the UK and Europe; this year, a British study found it among HIV-negative gay men too. Sexual transmission is linked to anal sex, fisting, the presence of other STDs and use of non-injected drugs like crystal. If you indulge, reach for condoms and latex gloves. C ya.  


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    chipper52
    Palm Springs
    California


    mtaj0818
    Washington
    DC


    jimmy807
    San Antonio
    Texas


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.